NCT00492050 2026-03-11
Bortezomib and Rituximab for Patients With Waldenstrom's Macroglobulinemia
M.D. Anderson Cancer Center
Phase 2 Active not recruiting
Clinical Trials
136 trialsNCT04151667 2026-03-11
Daratumumab Based Response Adapted Therapy for Older Adults With Newly Diagnosed Multiple Myeloma
H. Lee Moffitt Cancer Center and Research Institute
Phase 2 Active not recruiting
NCT01919086 2026-03-02
Response Adapted Therapy With Bortezomib/Dexamethasone Followed by Addition of Lenalidomide in Non Responders as Initial Treatment for Patients With Multiple Myeloma
Memorial Sloan Kettering Cancer Center
Phase 2 Completed
NCT00378105 2026-02-24
Bortezomib, Lenalidomide and Dexamethasone Combination Therapy in Patients With Newly Diagnosed Multiple Myeloma
Dana-Farber Cancer Institute
Phase 1/2 Active not recruiting
NCT01208662 2026-01-22
DFCI 10-106
Dana-Farber Cancer Institute
Phase 3 Active not recruiting
NCT02441686 2026-01-13
Phase II Study of Efficacy and Safety of Lenalidomide, Subcutaneous Bortezomib and Dexamethasone Therapy for Newly Diagnosed Multiple Myeloma
Dana-Farber Cancer Institute
Phase 2 Completed
NCT02553460 2025-12-10
Total Therapy for Infants With Acute Lymphoblastic Leukemia (ALL) I
St. Jude Children's Research Hospital
Phase 1/2 Active not recruiting
NCT00310037 2025-10-28
Bortezomib After Combination Chemotherapy, Rituximab, and an Autologous Stem Cell Transplant in Treating Patients With Mantle Cell Lymphoma
Alliance for Clinical Trials in Oncology
Phase 2 Completed
NCT01241708 2025-09-17
(Mel/MelVel)
Hackensack Meridian Health
Phase 3 Completed
NCT00410423 2025-04-30
Study of VELCADEĀ® With Mitoxantrone and Etoposide for Leukemias
Thomas Jefferson University
Phase 1/2 Completed
NCT02224729 2025-04-30
Bendamustine Hydrochloride, Bortezomib, and Dexamethasone in Treating Patients With Newly Diagnosed Multiple Myeloma
Thomas Jefferson University
Phase 2 Completed
NCT02375555 2024-10-01
Study of Bortezomib,Lenalidomide,Dexamethasone & Elotuzumab in Newly Diagnosed MM
Dana-Farber Cancer Institute
Phase 2 Completed
NCT00863369 2024-03-20
Bortezomib and Gemcitabine in Treating Patients With Relapsed B-Cell Non-Hodgkin Lymphoma
City of Hope Medical Center
Phase 1/2 Completed
NCT00520767 2023-12-22
Bortezomib, Melphalan, and Dexamethasone in Treating Patients With Primary Amyloidosis or Light Chain Deposition Disease
Barbara Ann Karmanos Cancer Institute
Phase 2 Completed
NCT00734149 2023-11-07
MVP
Duke University
Phase 2 Completed
NCT01177683 2023-10-06
Bendamustine in Combination With Bortezomib and Pegylated Liposomal Doxorubicin for Multiple Myeloma
Hoosier Cancer Research Network
Phase 1/2 Terminated
NCT00571493 2023-09-28
VELCADEĀ®-BEAM and Autologous Hematopoietic Stem Cell Transplantation for Non-Hodgkin's Lymphoma, or Mantle Cell Lymphoma
University of Nebraska
Phase 1/2 Completed
NCT01267812 2023-07-27
Bortezomib and Rituximab in Treating Patients With Mantle Cell Lymphoma Who Have Previously Undergone Stem Cell Transplantation
City of Hope Medical Center
Phase 2 Completed
NCT01860170 2023-06-02
Post-Transplant Bortezomib and High Dose Cyclophosphamide as Graft-Versus-Host Disease (GVHD) Prophylaxis
Corewell Health West
Phase 1/2 Completed
NCT00784823 2022-08-11
Mel-Vel
Hackensack Meridian Health
Phase 1/2 Completed
NCT00464178 2022-07-20
A Phase II Study of Bevacizumab and Bortezomib in Patients With Relapsed/Refractory Multiple Myeloma
Hackensack Meridian Health
Phase 2 Terminated
NCT01453101 2022-05-25
Flu-Mel-Vel
Hackensack Meridian Health
Phase 2 Completed
NCT01849783 2022-05-11
Autologous Stem Cell Transplant Followed By Maintenance Therapy in Treating Elderly Patients With Multiple Myeloma
University of Iowa
Phase 2 Completed
NCT00477412 2022-01-28
Bortezomib, Rituximab and Combination Chemotherapy in Treating Participants With Mantle Cell Lymphoma
M.D. Anderson Cancer Center
Phase 1/2 Completed
NCT02424851 2022-01-27
OPTIMAL
Oxford University Hospitals NHS Trust
Phase 2 Completed
NCT00479167 2021-11-04
A Phase II Trial of Combined Weekly Bortezomib and Tositumomab I-131 in Patients With Relapsed or Refractory Follicular Non-Hodgkin's Lymphoma
Rush University Medical Center
Phase 2 Terminated
NCT02481934 2021-08-20
NK-VS-MM
Hospital Universitario 12 de Octubre
Phase 1 Completed
NCT00792142 2021-08-19
Bortezomib, Thalidomide, and Dexamethasone After Melphalan and Stem Cell Transplant in Treating Patients With Stage I-III Multiple Myeloma
City of Hope Medical Center
Phase 2 Completed
NCT02703779 2021-06-18
Exploratory Trial to Estimate Proportion of Patients With Tumor Cell Contaminated Leukapheresis Products With and Without Bortezomib With In-vivo Purging - Multiple Myeloma (MM)
University of Kansas Medical Center
Phase 2 Completed
NCT02037256 2021-05-10
Bortezomib and Filgrastim to Promote Stem Cell Mobilization in Patients With Non-Hodgkin Lymphoma or Multiple Myeloma
Barbara Ann Karmanos Cancer Institute
Phase NA Completed
NCT01125293 2021-04-23
Everolimus, Bortezomib and/or Rituximab in Patients With Relapsed/Refractory Waldenstrom's Macroglobulinemia
Dana-Farber Cancer Institute
Phase 1/2 Terminated
NCT01736943 2021-02-24
Bortezomib and Doxil for the Treatment of Patients With Acute Myelogenous Leukemia
University of California, Davis
Phase 2 Completed
NCT00422799 2020-10-27
Combination Bortezomib and Rituximab in Patients With Waldenstrom's Macroglobulinemia (WM)
Dana-Farber Cancer Institute
Phase 2 Completed
NCT01083316 2020-09-25
Bortezomib and Dexamethasone Followed by High-Dose Melphalan and Stem Cell Transplantation for Primary (AL) Amyloidosis
Boston Medical Center
Phase 2 Completed
NCT00469209 2020-09-24
Velcade, Trisenox, Vitamin C and Melphalan for Myeloma Patients
M.D. Anderson Cancer Center
Phase 1/2 Completed
NCT01090921 2020-09-09
Safety and Efficacy Study of Single Weekly Bortezomib in Newly Diagnosed Multiple Myeloma
Boston VA Research Institute, Inc.
Phase 2 Completed
NCT00276614 2020-09-01
Bortezomib in Treating Patients With Metastatic Kidney Cancer
Jonsson Comprehensive Cancer Center
Phase 2 Completed
NCT00998010 2020-08-28
Bortezomib, Temozolomide, and Regional Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma Multiforme or Gliosarcoma
Jonsson Comprehensive Cancer Center
Phase 2 Completed
NCT01605032 2020-08-20
Busulfan, Melphalan, and Bortezomib Before First-Line Stem Cell Transplant in Treating Patients With Multiple Myeloma
Albert Einstein College of Medicine
Phase 2 Completed
NCT00084747 2020-08-17
Adjuvant Bortezomib Maintenance Therapy After Autologous Peripheral Stem Cell Transplantation in Treating Patients With Intermediate or Advanced Multiple Myeloma
Jonsson Comprehensive Cancer Center
Phase 1/2 Completed
NCT01833143 2020-08-04
Bortezomib in KRAS-Mutant Non-Small Cell Lung Cancer in Never Smokers or Those With KRAS G12D
Memorial Sloan Kettering Cancer Center
Phase 2 Completed
NCT00182637 2020-08-03
Bortezomib in Treating Patients With Relapsed or Refractory Cutaneous T-Cell Lymphoma
Jonsson Comprehensive Cancer Center
Phase 2 Completed
NCT00985907 2020-06-17
DMV
University of California, San Francisco
Phase 1/2 Terminated
NCT01212952 2020-04-17
Pomalidomide, Bortezomib, and Dexamethasone in Treating Patients With Relapsed or Refractory Multiple Myeloma
Mayo Clinic
Phase 1/2 Completed
NCT01383759 2020-04-07
Bortezomib/Dexamethasone (BD), Followed By Autologous Stem Cell Transplantation and Maintenance Bortezomib/Dexamethasone For the Initial Treatment of Monoclonal Immunoglobulin Deposition Disease (MIDD) Associated With Multiple Myeloma and AL Amyloidosis
Memorial Sloan Kettering Cancer Center
Phase NA Completed
NCT01504477 2020-03-16
Panitumumab and Bortezomib for Patients With Advanced Colorectal Cancer
Georgetown University
Phase 1/2 Terminated
NCT01438177 2020-02-24
Chloroquine in Combination With VELCADE and Cyclophosphamide for Relapsed and Refractory Multiple Myeloma
NYU Langone Health
Phase 2 Terminated
NCT00793572 2020-01-22
Autologous or Syngeneic Stem Cell Transplant Followed by Donor Stem Cell Transplant and Bortezomib in Treating Patients With Newly Diagnosed High-Risk, Relapsed, or Refractory Multiple Myeloma
Fred Hutchinson Cancer Center
Phase 2 Completed
NCT00980395 2019-12-30
VCR
University of Arizona
Phase 2 Completed
NCT01146834 2019-12-27
Trial of Three Stem Cell Mobilization Regimens for Multiple Myeloma
Weill Medical College of Cornell University
Phase 3 Completed